Abstract | BACKGROUND AND OBJECTIVES:
Clozapine is considered to be particularly effective in the treatment of dually diagnosed (DD) patients with psychosis and substance use disorders. However, its use is restricted by potentially severe side effects. The aim of the present pilot study was to compare the effects of clozapine with the newer second generation antipsychotic (SGA) ziprasidone in DD-patients. METHODS: RESULTS: Cannabis use was reduced in both groups during follow-up. Clozapine treatment was associated with less positive symptoms of schizophrenia, more side effects and poorer compliance with treatment. CONCLUSIONS: Results from this small pilot RCT suggest beneficial effects of both clozapine and ziprasidone in the treatment of cannabis use disorders in psychotic patients. Larger-scale RCTs are needed in order to assess advantages and disadvantages of the different SGAs in dually diagnosed populations.
|
Authors | Thomas Schnell, Dagmar Koethe, Anna Krasnianski, Stefanie Gairing, Knut Schnell, Jörg Daumann, Euphrosyne Gouzoulis-Mayfrank |
Journal | The American journal on addictions
(Am J Addict)
2014 May-Jun
Vol. 23
Issue 3
Pg. 308-12
ISSN: 1521-0391 [Electronic] England |
PMID | 24628830
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © American Academy of Addiction Psychiatry. |
Chemical References |
- Antipsychotic Agents
- Piperazines
- Thiazoles
- ziprasidone
- Clozapine
|
Topics |
- Adult
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Clozapine
(adverse effects, therapeutic use)
- Diagnosis, Dual (Psychiatry)
- Female
- Humans
- Male
- Marijuana Abuse
(complications, drug therapy)
- Medication Adherence
- Pilot Projects
- Piperazines
(adverse effects, therapeutic use)
- Schizophrenia
(complications, drug therapy)
- Thiazoles
(adverse effects, therapeutic use)
- Treatment Outcome
- Young Adult
|